Publications
Detailed Information
CKD-602, a camptothecin derivative, inhibits proliferation and induces apoptosis in glioma cell lines
Cited 16 time in
Web of Science
Cited 15 time in Scopus
- Authors
- Issue Date
- 2009-06
- Publisher
- SPANDIDOS PUBL LTD
- Citation
- ONCOLOGY REPORTS; Vol.21 6; 1413-1419
- Keywords
- belotecan ; camptothecin analogue ; CKD-602 ; topoisomerase 1 inhibitor ; malignant glioma
- Abstract
- CKD-602 7-[2-(N-isopropylamino)ethyl]-(20S)camptothecin, belotecan) is a synthetic water-soluble camptothecin derivative and topoisornerase inhibitor that has been shown to have clinical anticancer effect against ovarian and lung cancer. We studied its anticancer effects oil four human glioma cell lines, U87 MG, U343 MG, U251 MG and LN229. Cell viability was quantified by a modified 2-(2-methoxy-4-methoxy)-3-(4-nitropheyl)-5-(2,4-disulfophellyl) -2H-tetrazolium, monosodium salt and significant time- and dose-dependent cytotoxicity was observed in all cell lines. Susceptibility to CKD-602 at 48 h after treatment varied among the four cell lines and their IC(50) value was as follows: 9.07 nM (95% CI 0.18-37.42) for LN229, 14.57 nM (95% Cl 0.86-47.33) for U251 MG, 29.13 nM (95% CI 0.35-101.23) for U343 MG, and 84.66 nM (95% CI 34.63-148.25) for U87 MG. CKD-602 induced cell cycle arrest at G2 phase and produced antiproliferative activity and apoptosis in all cell lines. Thus, CKD-602 showed a significant anticancer effect on glioma cells in vitro and is a promising candidate for further studies on malignant gliomas.
- ISSN
- 1021-335X
- Language
- English
- Files in This Item:
- There are no files associated with this item.
- Appears in Collections:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.